• Vivos Therapeutics Inc VVOS.OQ reported a quarterly adjusted loss of 45 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.63. The mean expectation of two analysts for the quarter was for a loss of 40 cents per share. Wall Street expected results to range from -44 cents to -36 cents per share.

• Revenue fell 11.8% to $3.02 million from a year ago; analysts expected $3.67 million.

• Vivos Therapeutics Inc's reported EPS for the quarter was a loss of 45 cents​.

• The company reported a quarterly loss of $3.86 million.

• Vivos Therapeutics Inc shares had risen by 6.7% this quarter and lost 29.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.4% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

• Wall Street's median 12-month price target for Vivos Therapeutics Inc is $5.85

This summary was machine generated from LSEG data May 15 at 08:59 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)